China Montelukast Intermediate Market Size & Outlook, 2026-2034
China Montelukast Intermediate Market Insights
- According to Reed Intelligence analysis, the China Montelukast Intermediate Market size was USD 0.73 Million in 2025 and is projected to reach USD 1.09 Million by 2034.
- The China market is projected to grow at a CAGR of 4.58% between 2026 and 2034.
- By segment, GMP emerged as the largest By Type in terms of market size in 2025.
- GMP is anticipated to remain the most attractive By Type segment, recording the fastest growth during the forecast period.
![China Montelukast Intermediate Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/china-montelukast-intermediate-market-china-by-type-237378.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- China contributed 9.21% to the global Montelukast Intermediate Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Montelukast Intermediate Market.
- In Asia Pacific, China is projected to capture the leading share of market size by 2034.
- Among Asia Pacific markets, Japan is expected to post the fastest growth, reaching USD 0.39 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 0.73 Million |
| Market Size In 2034 | USD 1.09 Million |
| Largest segment | GMP |
| Units | Revenue in USD Million |
| CAGR | 4.58% (2026-2034) |
| Segmnetation Covered | |
| By Type |
|
| By Applications |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
China Montelukast Intermediate Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMP | XX.x | XX.x | XX.x | 0.46 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-GMP | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Montelukast Intermediate Market By Applications 2026-2034 (USD Million)
| By Applications | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asthma | XX.x | XX.x | XX.x | 0.32 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bronchospasm | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Allergic Rhinitis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Urticaria | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Montelukast Intermediate Market By End-User 2026-2034 (USD Million)
| By End-User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Biotechnological Companies | XX.x | XX.x | XX.x | 0.4 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.